Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RXST
SELLFLAGRxSight, Inc. · Healthcare · United States · $231M · Avg Vol: $4M/d
RxSight manufactures light-adjustable intraocular lenses for cataract surgery. The product has a strong real-world demand signal and a unique technological moat, but the company is still scaling toward consistent profitability and high ROIC.
COMPANY DESCRIPTION
RxSight, Inc. develops and commercializes the Light Adjustable Lens™ (LAL) system, a proprietary intraocular lens and light delivery device designed for cataract surgery that allows post-operative adjustment of the lens power. This innovative technology provides a distinct competitive advantage in the premium IOL market by addressing residual refractive errors, positioning RxSight as a niche leader in enhancing post-cataract surgery visual outcomes.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 49.0M | 89.1M | 139.9M | 134.5M | 40.0% |
| EPS | — | -2.41 | -1.41 | -0.71 | -0.95 | — |
| Shares | — | 28.3M | 36.1M | 40.4M | 41.2M | +45.9% |
| Debt | 39.8M | 45.0M | 3.0M | 12.3M | 11.0M | -27.4% |
| Equity | — | 89.9M | 160.4M | 281.2M | 275.7M | 45.3% |
| Op CF | — | -58.9M | -41.6M | -16.9M | -15.5M | — |
| Inv CF | — | 40.0M | -22.1M | -99.3M | 16.9M | — |
| Fin CF | — | 6.3M | 61.5M | 123.3M | 1.9M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RXST are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RXST | RxSight, Inc.(you) | $231M | 24 | SELL |
| TMCI | Treace Medical Concepts, Inc. | $200M | 29 | SELL |
| SGHT | Sight Sciences, Inc. | $275M | 16 | STRONG SELL |
| LUCD | Lucid Diagnostics Inc. | $200M | 15 | STRONG SELL |
| MXCT | MaxCyte, Inc. | $125M | 24 | SELL |
| QSI | Quantum-Si incorporated | $261M | 12 | STRONG SELL |
| CATX | Perspective Therapeutics, Inc. | $462M | 25 | SELL |
| LAB | Standard BioTools Inc. | $445M | 22 | SELL |
| TLSI | TriSalus Life Sciences, Inc. | $201M | 11 | STRONG SELL |
| CLPT | ClearPoint Neuro, Inc. | $367M | 17 | STRONG SELL |
Peer medians: ROE -22.7% · P/E 25.3x · Gross margin 44.3%